Béchir BEN HADJ YAHIA

Franchise Head (Integrated Strategy Leader) - Onco Lung @Roche

[Ministère de la Santé @Sante_Gouv]

#Bronchiolite | L'épidémie de bronchiolite se poursuit sur le territoire 👶

Respectez les bons gestes pour protéger votre bébé même pendant les fêtes ⤵

➕ d'infos : https://t.co/Tz9VVqXpLu

[Béchir BEN HADJ YAHIA @BechirBhy]

To learn more about our 7-year heritage as @Roche, building awareness about #lungcancer, see my post: https://t.co/ql5JdtGkmT
For #LCAM23, our new Campain is now launched, in collaboration with @reseauKpoumon, @delairasso, l'APOP Foch and @AlkRos1France : https://t.co/1sZ4Cg3Ngd

[Béchir BEN HADJ YAHIA @BechirBhy]

#ESMO23 is coming soon! @Roche oncology teams will be there to share with you our advances in science and solutions for patients. To learn more about our commitments, find my post here : https://t.co/AIQpObI6V2 @myESMO #congress

[IFCT lung @IFCTlung]

CLINATEZO (518 pts) and LURBICLIN (312 pts) #RWE studies confirm effectiveness and safety of #atezolizumab and #lurbinectedin in real-life setting #SCLC #ASCO23
Congrats to IFCT RWE taskforce with @nicogirardcurie and L. Falchero.
https://t.co/EGp4DPcAoL
https://t.co/DqbcIsUwv2

[Béchir BEN HADJ YAHIA @BechirBhy]

#ASCO23

Innovation is our DNA!

Toute l’équipe Poumon Roche France est à votre disposition !

Venez à notre rencontre sur le stand Roche/Genentech.

Michael Lukasiewicz, Léa Emonnot, Katia Thokagevistk Desroziers & Javier Chinchilla

[Béchir BEN HADJ YAHIA @BechirBhy]

@PhilippeSafire Bravo mon ami ! 😎😘😘

[Béchir BEN HADJ YAHIA @BechirBhy]

So glad to be back in the Lung Cancer space! Can’t wait to see you in person at ESMO in Paris++

[Béchir BEN HADJ YAHIA @BechirBhy]

@FAndreMD @GustaveRoussy 👍

[Béchir BEN HADJ YAHIA @BechirBhy]

Bright talk by @JeromeGalon clarifying the understanding of immune response evolution along with tumor progression at FITC 1st annual meeting @institut_curie #cancer #immunotherapy

[Béchir BEN HADJ YAHIA @BechirBhy]

When science meets patients needs...

Excellent introduction by Aurélien Marabelle to the 1st FITC (Société Française d’Immuno-Thérapie du Cancer) annual meeting!

Ambitious program for this event at Institut Curie today!

https://t.co/9btiwKLjq5

#cancer #immunotherapy

[Béchir BEN HADJ YAHIA @BechirBhy]

Live from @PrixGalien! Since 1970s, this Prize celebrates innovation in the fields of healthcare, research, drug & medical device++ The best is yet to come!

[Fabrice Barlesi @barlesi]

Second time for ‘The Early Phase Trials of the Year’ starting with NTRK inhibitors in pediatric cancers by @aphm_actu CEPCM CLIP2 @APHMphaseIonco @univamu A molecular alteration to be screened in every of our young patients

[Roche @Roche]

We had the pleasure of connecting with the oncology community at #ESMO19. Hear Cindy talk about the best part so far and why collaboration is vital.

[Fabrice Barlesi @barlesi]

Impressive updated median PFS on ALK+ #LCSM patients on Alectinib almost 35 months presented by Filippo de Marinis #CIOT19

[Béchir BEN HADJ YAHIA @BechirBhy]

@FAndreMD @TheLancet 😂

[Béchir BEN HADJ YAHIA @BechirBhy]

@barlesi @jpaArmand @aphm_actu @univamu @APHMphaseIonco 40 years of history !

[Fabrice Barlesi @barlesi]

Clinical trials design w/o modeling! By Joseph CICCOLINI @univamu @aphm_actu #8eseminairephaseIAPHM

[Béchir BEN HADJ YAHIA @BechirBhy]

Introduction of the « 8éme séminaire CEPCM CLIP² » by @barlesi today at Marseille. Stay tuned!

[Béchir BEN HADJ YAHIA @BechirBhy]

Very nice overview of Breast Cancer treatment with first immunotherapy in TNBC metastatic setting, by Dr Marie Robert at French Editor’s Best of ASCO session #ASC019

[National Cancer Institute @theNCI]

In the Pediatric MATCH trial, 24% of young patients with advanced cancers were eligible to receive one of the targeted therapies being evaluated: https://t.co/JBHoBcH5ZH @ASCO #ASCO19